Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa Study of SR-Exenatide (PT320) in Early Parkinson's Disease
KCT0004652Phase 2Recruiting
- Sponsor
- Peptron Inc.
- Start
- Mar 2020
- Modality
- Peptides, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing SR-Exenatide (PT320) with Placebo (2 arms). Started Mar 2020; status: recruiting.
02
Drugs
exenatide implant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on KCT0004652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004652.